Analyzing the Price-to-Earnings Ratio of Ampio Pharmaceuticals Inc (AMPE)

The 36-month beta value for AMPE is also noteworthy at 1.95. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for AMPE is 1.10M, and at present, short sellers hold a 2.98% of that float. The average trading volume of AMPE on April 04, 2024 was 175.68K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

AMPE) stock’s latest price update

The stock of Ampio Pharmaceuticals Inc (AMEX: AMPE) has increased by 15.15 when compared to last closing price of 0.80.Despite this, the company has seen a gain of 13.52% in its stock price over the last five trading days. PRNewsWire reported 2023-09-26 that ENGLEWOOD, Colo., Sept. 26, 2023 /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the “Company”) a pre-revenue stage biopharmaceutical Company focused on development of a potential treatment for osteoarthritis as part of its OA.201 program, today announced that its CEO, Michael A.

AMPE’s Market Performance

Ampio Pharmaceuticals Inc (AMPE) has experienced a 13.52% rise in stock performance for the past week, with a -41.70% drop in the past month, and a -55.71% drop in the past quarter. The volatility ratio for the week is 20.31%, and the volatility levels for the past 30 days are at 11.70% for AMPE. The simple moving average for the past 20 days is -36.18% for AMPE’s stock, with a -69.12% simple moving average for the past 200 days.

AMPE Trading at -43.66% from the 50-Day Moving Average

After a stumble in the market that brought AMPE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.90% of loss for the given period.

Volatility was left at 11.70%, however, over the last 30 days, the volatility rate increased by 20.31%, as shares sank -41.70% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -43.83% lower at present.

During the last 5 trading sessions, AMPE rose by +13.52%, which changed the moving average for the period of 200-days by -82.37% in comparison to the 20-day moving average, which settled at $1.4106. In addition, Ampio Pharmaceuticals Inc saw -55.06% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at AMPE starting from BUCHI J KEVIN, who purchase 21,858 shares at the price of $0.29 back on Jun 09 ’23. After this action, BUCHI J KEVIN now owns 146,858 shares of Ampio Pharmaceuticals Inc, valued at $6,284 using the latest closing price.

BUCHI J KEVIN, the Director of Ampio Pharmaceuticals Inc, purchase 25,000 shares at $0.30 during a trade that took place back on Jun 08 ’23, which means that BUCHI J KEVIN is holding 125,000 shares at $7,400 based on the most recent closing price.

Stock Fundamentals for AMPE

The total capital return value is set at -1.85. Equity return is now at value -113.96, with -89.34 for asset returns.

Based on Ampio Pharmaceuticals Inc (AMPE), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -29.14. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 23.83.

Currently, EBITDA for the company is -8.63 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.36.

Conclusion

In summary, Ampio Pharmaceuticals Inc (AMPE) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts